{
  "pmcid": "10027760",
  "sha256": "18044ab44c2dd5c14e8cd445ed81330a153717f12bf6fee5f05e05438166df17",
  "timestamp_utc": "2025-11-09T15:04:38.566425+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 13.65089285714286,
    "reading_ease": 26.803482142857177,
    "word_count": 266
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "A total of 15 pediatric patients with melanoma, squamous cell carcinoma, and sarcoma were prospectively included."
      },
      "Participants": {
        "score": 2,
        "evidence": "15 pediatric patients with melanoma, squamous cell carcinoma, and sarcoma were prospectively included."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Preoperatively, patients were injected with ICG–TC and imaging with lymphoscintigraphy and single-photon emission computed tomography– computed tomography was performed."
      },
      "Objective": {
        "score": 1,
        "evidence": "our aim is to determine the feasibility of the addition of ICG to 99m technetium nanocolloid (ICG–TC) for visual detection of SLN in pediatric patients."
      },
      "Method_Outcome": {
        "score": 1,
        "evidence": "Postoperatively, fluorescence was quantified by tumor-to-background ratio (TBR) and surgeons evaluated the use of ICG using a standardized questionnaire."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "A total of 15 pediatric patients with melanoma, squamous cell carcinoma, and sarcoma were prospectively included."
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "In 10/15 (67%) patients, SLNs were visible transcutaneously. Of all intraoperatively detected SLNs, 35/37 (95%) were fluorescent and 37/37 (100%) were radioactive."
      },
      "Harms": {
        "score": 1,
        "evidence": "no adverse events occurred."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 11,
    "max_score": 25
  }
}